Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of certolizumab pegol in adult-onset active and progressive psoriatic arthritis
2009-011720-59Phase 3Completed
- Sponsor
- UCB
- Start
- Feb 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in psoriatic arthritis (PsA) (3 arms), sponsored by UCB. Primary endpoint: Primary efficacy variables. Started Feb 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2009-011720-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011720-59.